Cynata Therapeutics' (ASX:CYP) lead asset, CYP-001, could see an upward revision in its pricing assumptions if the launch of Mesoblast's (ASX:MSB) Ryoncil sets a high market precedent, according to a Feb.10 note by Euroz Hartleys.
Based on estimates, Ryoncil could be priced between $500,000 and over US$1 million per patient.
Given that Ryoncil is the first US Food and Drug Administration-approved mesenchymal stem cell (MSC) therapy, its pricing may influence similar treatments, including CYP-001, Euroz added.
Euroz Hartleys notes that while CYP-001, is unlikely to match Ryoncil's pricing, a price of $1 million per patient for Ryoncil could prompt an upward revision of CYP-001's current price estimate of $150,000 per patient.
It maintained CYP's speculative buy rating and $0.67 price target.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.